Oral presentation
Search our science
Search our scientific publications and resources
on rare bleeding disorders
Scientific resources from Novo Nordisk
Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.
Search Results
We found 359 resources matching your search criteria
Audio poster
Vance MacDonald, Xin Ying Lee, Alexandre Caillaud, Maria Luckevich, Anthony Bentley; Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch. Blood 2020; 136 (Supplement 1): 19. doi: https://doi.org/10.1182/blood-2020-134236
Audio poster
Stephanie Valer Seremetis, Katarina Cepo, Josephine Skovgaard Rasmussen, Trine Høyer Rose, Søren Tamer, Thomas Porstmann, Jesper Haaning; Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events. Blood 2020; 136 (Supplement 1): 40. doi: https://doi.org/10.1182/blood-2020-139563
Audio poster
Amy D Shapiro, Giancarlo Castaman, Katarina Cepo, Sidsel Marie Tønder, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Guy Young, Silva Zupancic-Šalek, Victor Jimenez Yuste; Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Blood 2020; 136 (Supplement 1): 40–41. doi: https://doi.org/10.1182/blood-2020-139910
Audio poster
Trine Høyer Rose, Christian Hollensen, Henrik Agersø, Rune Viig Overgaard; A Population Pharmacokinetic Model for Concizumab Based on Phase 1 and Phase 2 Trial Data. Blood 2020; 136 (Supplement 1): 4. doi: https://doi.org/10.1182/blood-2020-140255
Audio poster
Marianne Kjalke, Søren Andersen; The in Vitro Effect on Thrombin Generation of Adding rFVIII or rFIX to Hemophilia a or b Plasma in the Absence or Presence of Concizumab. Blood 2020; 136 (Supplement 1): 22–23. doi: https://doi.org/10.1182/blood-2020-140272
Audio poster
Brian Lauritzen, Mads Bjelke, Marie Rossen, Mikala Skydsgaard, Marianne Kjalke, Olle Björkdahl, Stine L Kjellev; A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys. Blood 2020; 136 (Supplement 1): 26–27. doi: https://doi.org/10.1182/blood-2020-137006
Abstract
Vance MacDonald, Xin Ying Lee, Alexandre Caillaud, Maria Luckevich, Anthony Bentley; Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch. Blood 2020; 136 (Supplement 1): 19. doi: https://doi.org/10.1182/blood-2020-134236
Abstract
Stephanie Valer Seremetis, Katarina Cepo, Josephine Skovgaard Rasmussen, Trine Høyer Rose, Søren Tamer, Thomas Porstmann, Jesper Haaning; Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events. Blood 2020; 136 (Supplement 1): 40. doi: https://doi.org/10.1182/blood-2020-139563
Abstract
Amy D Shapiro, Giancarlo Castaman, Katarina Cepo, Sidsel Marie Tønder, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Guy Young, Silva Zupancic-Šalek, Victor Jimenez Yuste; Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Blood 2020; 136 (Supplement 1): 40–41. doi: https://doi.org/10.1182/blood-2020-139910
Abstract
Trine Høyer Rose, Christian Hollensen, Henrik Agersø, Rune Viig Overgaard; A Population Pharmacokinetic Model for Concizumab Based on Phase 1 and Phase 2 Trial Data. Blood 2020; 136 (Supplement 1): 4. doi: https://doi.org/10.1182/blood-2020-140255
Abstract
Marianne Kjalke, Søren Andersen; The in Vitro Effect on Thrombin Generation of Adding rFVIII or rFIX to Hemophilia a or b Plasma in the Absence or Presence of Concizumab. Blood 2020; 136 (Supplement 1): 22–23. doi: https://doi.org/10.1182/blood-2020-140272
Abstract
Brian Lauritzen, Mads Bjelke, Marie Rossen, Mikala Skydsgaard, Marianne Kjalke, Olle Björkdahl, Stine L Kjellev; A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys. Blood 2020; 136 (Supplement 1): 26–27. doi: https://doi.org/10.1182/blood-2020-137006
Review article
: Matsushita T, Mangles S. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A. J Thromb Haemost. 2020;18(Suppl. 1):26–33.
Primary manuscript
Giangrande, P, Abdul Karim, F, Nemes, L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. J Thromb Haemost. 2020; 18(Suppl. 1): 5– 14.
Primary manuscript
Giangrande, P, Abdul Karim, F, Nemes, L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. J Thromb Haemost. 2020; 18(Suppl. 1): 5– 14
Supplement article
Chowdary, P. (2020), N8?GP: A new extended half?life recombinant factor VIII product for hemophilia A. J Thromb Haemost, 18: 3-4.
Primary manuscript
Giangrande, P, Abdul Karim, F, Nemes, L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. J Thromb Haemost. 2020; 18(Suppl. 1): 5– 14. https://doi.org/10.1111/jth.14959
Primary manuscript
Chan AK, Alamelu J, Barnes C, et al. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost. 2020;00:1–13.
Poster
Trakymien SS, Shen C, Benchikh El Fegoun S, Landorph A. Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Poster
Hampton K, Clausen WHO, Benchikh El Fegoun S, Landorph A. Successful Multiple Surgeries in Adult Patients with Haemophilia A (HA) Treated With Turoctocog Alfa Pegol (N8-GP) in the Pathfinder 3 trial [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1).
Poster
Giangrande P, Lee XY, Curry N, Benchikh El Fegoun S. Prophylaxis with Turoctocog Alfa Pegol (N8-GP) Maintains Improvements in Health-Related Quality of Life (HRQoL) and Treatment Satisfaction (TS) over ?4.5 Years in Patients with Haemophilia A (HA) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1).
Audio poster
Matino D, Iorio A, Keepanasseril A, Germini F, Birkegård AC, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, Poon M-. A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Poster
Phua C, Faurby M, Macdonald V, Lambert J, Teitel J. A Real-World Qualitative Analysis of the Burden of Hemophilia B and Patient Experiences with Prophylactic Nonacog Beta Pegol [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1).